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The object of this article was to systematically review available methods to measure comorbidity and to assess their validity and reliability. A
search was made in Medline and Embase, with the keywords comorbidity and multi-morbidity, to identify articles in which a method to measure co-
morbidity was described. The references of these articles were also checked, and using a standardized checklist the relevant data were extracted from
these articles. An assessment was made of the content, concurrent, predictive and construct validity, and the reliability. Thirteen different methods to
measure comorbidity were identified: one disease count and 12 indexes. Data on content and predictive validity were available for all measures,
while data on construct validity were available for nine methods, data on concurrent validity, and interrater reliability for eight methods, and data on
intrarater reliability for three methods. The Charlson Index is the most extensively studied comorbidity index for predicting mortality. The Cumula-
tive Illness Rating Scale (CIRS) addresses all relevant body systems without using specific diagnoses. The Index of Coexisting Disease (ICED) has
a two-dimensional structure, measuring disease severity and disability, which can be useful when mortality and disability are the outcomes of inter-
est. The Kaplan Index was specifically developed for use in diabetes research. The Charlson Index, the CIRS, the ICED and the Kaplan Index are
valid and reliable methods to measure comorbidity that can be used in clinical research. For the other indexes, insufficient data on the clinimetric








As early as 1970, Alvan Feinstein noted that “the failure
to classify and analyze comorbid diseases has led to many
difficulties in medical statistics” [1], because comorbidity
can affect the moment of detection, prognosis, therapy, and
outcome. Comorbidity can play an important role in differ-
ent types of research. In etiologic studies the relationship
between comorbid conditions and an index disease can be
investigated. Comorbidity can be the cause or the conse-
quence of an index disease. It is also possible that the index
disease and the comorbid conditions share the same risk
factors. In diagnostic studies, comorbidity can obscure the
relationship between the test under study and the index dis-
ease. In these fields of research it might be particularly use-
ful to analyze every disease as a separate variable, to gain
insight into the relationship between individual diseases and
the index disease at issue. However, this method is not fea-
sible in small studies, because of reduced efficiency of the
analysis. Randomized controlled trials (RCTs) and prognos-
tic studies can also be complicated by comorbidity. Comor-
bidity can either act as a confounder, threatening the inter-
nal validity, or as an effect modifier, threatening the internal
and external validity of the study. For these purposes an ef-
ficient method is needed to measure comorbidity.
There are four important reasons for measuring comor-
bidity. The first reason is to be able to correct for confound-
ing, and thus improve the internal validity of studies. The
second reason is to be able to identify effect modification. A
third reason is the desire to use comorbidity as a predictor of
study outcome or natural history. Finally, a comprehensive
comorbidity measure, including many cooccurring comor-
bid conditions in one valid variable, is needed for reasons of
statistical efficiency.
Because an overview of available methods to measure co-
morbidity is still lacking, the following research question was
formulated: Which methods are available for measuring co-




A search was made in the electronic databases of Med-
line (from January 1966 to September 2000) and Embase
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(from January 1988 to September 2000). The following
keywords were used to identify potentially useful articles:
comorbidity, multimorbidity, and coexisting disease. Arti-
cles in which the focus was on comorbidity assessment or
comorbidity was an important (prognostic) variable were
considered for inclusion. In the literature several terms are
being used in comorbidity research. Also, there is no con-
sensus regarding the definition of these terms. This review
focuses on methods that can be used to assess the burden of
diseases that exists besides an index disease, i.e., the disease
under study. Subsequently, it was carefully checked
whether the articles described methods to assess comorbid-
ity or the clinimetric properties of these methods. Then, the
reference lists of the retrieved articles were checked for
other eligible articles. Methods that analyze every disease as
a separate variable were excluded. Because we focus on co-
morbidity in medical patients, methods that deal with psy-
chiatric comorbidity in populations in which the index dis-
ease (the main disease under study) is also psychiatric were
also excluded.
An assessment was made of the content, criterion, and
construct validity, as well as the reliability of the identified
methods [2]. As an indication of the administrative burden a
description of the information that is needed to arrive at a
score on the measure is given. Because the focus of this re-
view is on comorbidity as a determinant and not on comor-
bidity as an evaluative measure, responsiveness was not as-
sessed. Content validity concerns the extent to which a
measure includes all relevant items: it is a qualitative assess-
ment. To describe content validity a short description is given
of the items included in the method, whether or not some type
of weighting or (pathophysiologic) severity ranking was ap-
plied, which information is needed to obtain a score, how to
arrive at the final score, and whether or not adaptations of the
method are available for specific purposes.
Streiner and Norman [2] define criterion validity as: “the
correlation of a scale with some other measure of the trait or
disorder under study, ideally, a ‘gold standard’ (the crite-
rion) which has been used and accepted in the field.” Unfor-
tunately, there is no “gold standard” available for measuring
comorbidity in medical patients, so one has to use other co-
morbidity measures for comparison. In this situation the de-
cision on which measure is best depends not only on statisti-
cal tests but also on clinical judgement. Criterion validity
can be subdivided into concurrent and predictive validity.
Concurrent validity is assessed by correlating the measure
under study with the criterion measure, which is given at the
same time [2]. Parameters used to assess concurrent validity





the Intraclass Correlation Coefficient (ICC). Although it is
very difficult to determine cutoff points for correlation coef-
ficients, because there are many factors influencing their
value [2], correlation coefficients exceeding 0.40 were con-
sidered to be moderate and those exceeding 0.75 were con-
sidered to be high [3]. Predictive validity [2] is the ability of
a measure to predict future events or future scores on the
 
outcome measure of interest. The assessment of predictive
validity was based on parameters obtained from survival
analysis, proportional hazards models, and linear or logistic
regression models. Points of interest were the relative risks







), and the area under the receiver operating char-
acteristic curve (AUC). If regression models predicting fu-
ture events were significant or significantly improved after
adding the comorbidity measure under study, this was con-
sidered to support predictive validity.
The assessment of construct validity encompasses the
testing of hypotheses regarding the relationship of the mea-
sure under study with other more or less related traits (con-
structs) [2], such as age, mortality, ADL, length of stay, or
number of medications taken. There are several methods
that can be used to assess construct validity, such as correla-
tion coefficients and comparing means or proportions in dif-
ferent populations. Whether or not construct validity is con-
firmed will be discussed for every measure, because it is not
possible to formulate comprehensive rules for assessing
construct validity.
Different types of reliability were also investigated: test-
retest reliability, and intra- and interrater reliability. Para-
meters used to assess reliability are (in descending order of
appropriateness) [2] Intraclass Correlation Coefficients





), and percentage of reliability. Reliability coeffi-
cients are considered to be fair when they exceed 0.40 and
moderate when they exceed 0.75 [3].
For every identified method the first author (VdG)
screened all related articles for data regarding the clinimet-
ric properties of that method, using a standardized data-ex-
traction form. Every method was either classified as an “in-
dex” or as a “disease count.” Methods were classified as an
“index” if the authors used weights or (pathophysiologic)
severity rankings for the conditions or dimensions included
in the index. Methods were classified as a “disease count” if
the authors solely used an enumeration of the number of
conditions present. Methods that did not already have a
name were given the name of the first author and the cate-
gory to which they were assigned. For example, if the first
author’s name is Schwarz, and the method was classified as




Thirteen different methods to assess comorbidity were
identified and presented in alphabetical order in Table 1:
one disease count and 12 indexes. Data on content and pre-
dictive validity were available for all measures, while data
on construct validity were available for nine methods, data
on concurrent validity for eight methods, data on interrater
reproducibility for eight methods, and data on intrarater reli-
ability for three methods.
The Burden of Disease (BOD) index [4] consists of 59
weighted disease categories, selected on the basis of a litera-
 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ture review and a consensus meeting of three physicians and
a nurse. To obtain the score on the BOD Index, medical
records over the previous year were reviewed, based on
standardized guidelines assessing symptoms, complications
and need for and complexity of therapy. Although the clini-
metric data are obtained from one single article, they sup-
port the concurrent and predictive validity of the BOD [4].
Furthermore, the authors found a low, but positive relation-
ship with the Katz Activities of Daily Living scale (Katz
ADL), supporting construct validity [4]. There was no rela-
tionship with the Sickness Impact Profile (SIP), whereas a
weak positive relationship would be expected. Interrater re-
liability was good [4] (Table 1).
The Charlson Index [5] is the most extensively studied co-
morbidity index [4–26]. The 19 diseases included in the in-
dex have been selected and weighted on the basis of the
strength of their association with mortality. It has been
adapted for use with ICD-9 databases [7–13,15,22], for use
with patients with amputations [17], transformed into a ques-
tionnaire [6], and combined with age to form an age–comor-
bidity index [16]. Four out of six comparisons with other in-
dices of comorbidity yielded correlation coefficients
exceeding 0.40, supporting concurrent validity [4,18–22].
Predictive validity was confirmed by finding many signifi-
cant relationships of the Charlson index with various criterion
outcomes, such as mortality, disability, readmissions and
length of stay (Table 1) [5,7,10–14,16,17,19,22–25]. All rela-
tionships with various kinds of variables showed some, al-
though not perfect, correlations in the anticipated directions,
supporting construct validity [4,6,8,9,12,14,15,18–20,24,26].
Test-retest reliability is good, and interrater reliability is mod-





[6,14,18,20]. It should be noted that emphasis has been laid
on the ability of the index to predict mortality (Table 1).
The Cumulative Illness Rating Scale (CIRS) [27] rates 13,
conceptually valid, body systems (supporting content vali-
dity) on a five-point (pathophysiologic) severity scale. It has
been slightly adapted to form the CIRS-G (CIRS geriatric)
[28], for which guidelines to enhance reliability have been
formulated. Criterion validity has been confirmed by show-
ing high correlation coefficients when comparing CIRS
scores based on autopsy (the gold standard) with those based
on health histories and chart reviews [29]. The CIRS was cor-
related with four other measures of comorbidity. Three out of
five correlation coefficients exceeded 0.40, supporting con-
current validity [19,20,28]. There is little evidence to support
predictive validity [19,30]. Small to fair positive correlations
in the anticipated directions have been found for other vari-
ables, such as medication usage, ADL, IADL, and age, sup-
porting construct validity [20,28,31]. Interrater and test-retest
reliability are good [19,20,27,28] (Table 1).
The Cornoni-Huntley index was intended to be used in a
study investigating hypertension and associated comorbid
conditions [32]. Because the authors used data that were
gathered in another study, only information on visual acu-
ity, hearing ability, heart disease, stroke, and diabetes was
available. Based on this information, they constructed a
four-level comorbidity index. The limited data support the
predictive validity with mortality as outcome [32] (Table 1).
Several authors studied comorbidity by simply counting
the number of diseases that exist in addition to the index
disease of a patient [19,33–36]. Although this method
seems to be quite straightforward, substantial differences
exist with regard to the definitions used to define a condi-
tion as comorbid. Some authors used ICD-9 codes to count
the total number of comorbid conditions [19], whereas oth-
ers made up a list of carefully selected comorbid conditions
and counted the number of these conditions that were
present, using medical records or ICD-9-CM codes [33–35].
Gross et al. [36] defined a condition as being comorbid if it
required treatment or had altered an organ function. Three
out of five correlations with other comorbidity measures or
severity of illness measures exceeded 0.40, supporting con-
current validity [19,36]. Evidence from analyses based on
several different outcomes [33,35] supports predictive va-
lidity. Construct validity was studied by comparing scores
in two different groups showing expected differences
[19,33] and relationships with several other variables show-
ing small but positive associations in the anticipated direc-
tions [34,36] (Table 1).
The Duke Severity of Illness (DUSOI) index [37] was
developed to assess ambulatory primary care patients, based
on patient records, but has also been modified so that it can
be used in direct contact between patient and clinician.
First, all health problems are identified. For every health
problem four domains (symptoms, complications, prognosis
without treatment, and treatability) are rated on a five-point
scale. The data support concurrent [37], predictive [38], and
construct [37] validity. Test-retest [37] and interrater reli-
ability [37–39] are fair, and intrarater reliability is fair to
good [37–39] (Table 1).
The Hallstrom index was specifically developed to assist
in predicting the outcome of cardiac arrest [40]. It consists
of a chronic factor (CF) and a symptom factor (SF). The CF
is the number of present conditions from a set of 10 condi-
tions, and the SF is the number of present symptoms from a
set of six symptoms related to cardiac disease. A low rank




.001), suggesting that the two scales assess two different
concepts. The limited available data provide some support
for predictive and construct validity [40] (Table 1).
The Hurwitz index was used in a study that was designed
to assess the influence of comorbidity on the type of care
(primary, specialist, chiropractic or other) that patients seek
for their back problems [41]. Every patient was classified as
having either no comorbidity, nondisabling comorbidity, or
disabling comorbidity. The index was only able to distin-
guish between medical and chiropractic care, thus providing
limited support for predictive validity [41] (Table 1).
The Index of Coexistent Disease (ICED) [42] consists of
two different dimensions, one measuring the disease sever-
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one measuring the “overall functional severity” (disability)
caused by comorbidity (ICED-FS). Scores are based on an
explicit list of symptoms, signs, and laboratory tests. All in-
formation contained in a medical chart can be used to calcu-
late a score. The data support concurrent [4,21,42] and pre-
dictive validity [42]. Intrarater reliability is good, and
interrater reliability is fair [42,43] (Table 1).
The Incalzi index consists of 52 conditions, each
weighted according to its relative risk (RR) for mortality
[44]. An Incalzi age index can be computed by adding two,
three, or four points to the score of patients aged 76 to 85
years, 86 to 95 years, and over 95 years, respectively [44].
Predictive validity was shown for both the dichotomized
(cutoff values were identified on ROC curves) Incalzi and
the Incalzi age index for predicting mortality. Showing that
the mortality rate for patients with scores above the 75th
percentile was higher than for those with scores under the
75th percentile provide further support [44]. According to
the authors, interrater reliability was good (data not pre-
sented in their article) [44] (Table 1).
The Kaplan index uses two forms of classification, fo-
cusing on the type of comorbidity and the pathophysiologic
severity of the present comorbid conditions, respectively.
The type of comorbidity can be classified as vascular (hy-
pertension, cardiac disorders, peripheral vascular disease,
retinopathy, and cerebrovascular disease) or nonvascular
(lung, liver, bone, and nondiabetic renal diseases). Patho-
physiologic severity is rated on a four-point scale, ranging
from 0 (no, or easy to control comorbidity) to 3 (recent full
decompensation of comorbid condition). The rating of the
most severe condition determines the overall comorbidity
score. Scores for vascular and nonvascular comorbidity can
be calculated, based on the most severe condition in each
subscale. There are two adaptations, the Modified Medical
Comorbidity Index (MMCI) and the Adult Comorbidity
Evaluation 27 (ACE-27), available [45,46]. Although the
adaptations look promising, there are, to our knowledge, no
articles published in which a detailed description of either
the (content) validity or the reliability is given. The ability
of the Kaplan index to predict mortality was studied
[5,14,47]. The results support predictive validity (Table 1).
The Liu index consists of 38 conditions, and was specifi-
cally constructed for use in stroke outcome research [18].
Every condition is rated on a six-point scale, ranging from 0
(not present) to 5 (active rehabilitation is contraindicated).
The Liu index has been compared with the Charlson index,
yielding a borderline fair correlation [18]. This result pro-
vides some support for concurrent validity, because, given
the different objective of the Charlson index, this correla-
tion should neither be too low nor too strong. The Liu index
is able to predict scores on the Functional Independence
Measure (FIM) and Length of Stay (LOS), supporting pre-
dictive validity [18]. Fair correlation coefficients in the an-
ticipated directions between the Liu index and some other
variables provide support for construct validity [18,48]. In-
terrater reliability is good [18] (Table 1).
The Shwarz index consists of 21 weighted conditions,
selected from 52 conditions that were derived from the liter-
ature on the basis of their positive relationship with mortal-
ity or their negative influence on the treatment of the pri-
mary condition, using a regression model that was made to
predict costs [49]. The Shwarz index can be used with med-
ical records and with databases that use ICD-9-CM codes.
Data supporting predictive validity were obtained from re-
gression models predicting costs for the Shwartz index [49],
using subgroup analyses and other data sets [49]. Models
based on data from medical records performed better than
models based on ICD-9-CM codes [49]. According to the
authors, intrarater reliability was high (data not presented in




Measuring comorbidity is an aspect of research that is re-
ceiving increasing attention in the literature. Several authors
have discussed and compared the use of various selected
methods to measure comorbidity [50–53]. This review de-
scribes methods that can be used to measure comorbidity in
clinical research, without limiting the focus to certain index
diseases or diagnostic groups. Thirteen different methods
were identified. Six indexes used a carefully developed list
of clearly defined diagnoses (BOD, Charlson Index, Hall-
strom Index, Incalzi Index, Liu Index, and Shwartz Index).
Three indexes rated comorbidity burden by using a system
that assessed the effect of comorbid conditions on specific
body systems (CIRS, ICED, and Kaplan Index). Two in-
dexes rated comorbidity on a three- or four-point scale us-
ing very broad categories (Cornoni-Huntley Index and Hur-
witz Index). Two methods used every present condition to
calculate a score: one simply counted the number of present
comorbid conditions (Disease count) and the other calcu-
lated a summary score based on weighted scores for every
present comorbid condition (DUSOI).
Although all these methods were developed to measure
comorbidity, in the current literature there is no consensus
regarding the definition of comorbidity. According to Fein-
stein [1], comorbidity is defined as “any distinct additional
entity that has existed or may occur during the clinical
course of a patient who has the index disease under study.”
Another definition of comorbidity is the cooccurrence of
multiple diseases in one person [51]. In this respect, Van
den Akker et al. [54] made a useful distinction between, on
the one hand, multimorbidity (i.e., the cooccurrence of mul-
tiple chronic or acute diseases and medical conditions in
one person) and, on the other hand, comorbidity as defined
by Feinstein [1]. By definition, for research on multimor-
bidity no index disease is used, whereas for comorbidity re-
search an index disease is obligatory. Some of the methods
identified can be used for both purposes, depending on
whether the focus in on measuring the total burden of dis-
eases in a patient (generic multimorbidity measures) or the
burden of comorbid diseases in addition to the condition of
 




interest (generic comorbidity measures). In the latter case
the index disease is omitted from the comorbidity measure-
ment. Other methods, such as the Kaplan, the Liu, the Cor-
noni-Huntley, and the Hallstrom indexes, were specifically
developed to measure comorbid diseases in addition to one
specific index disease (disease specific comorbidity mea-
sures). The other nine methods are generic measures.
Comorbidity indexes first identify the present comorbid dis-
eases and subsequently apply weights or (pathophysiologic) se-
verity ratings for these diseases. The technique of applying
weights or (pathophysiologic) severity ratings is very valuable.
There is evidence that correcting for comorbidity by simply
counting the number of existing diseases leads to another con-
clusion, than correcting for comorbidity by comorbidity indexes
that use weights or (pathophysiologic) severity ratings [55].
Although there is a growing body of evidence that comor-
bidity, as a disease count or an index, is an independent predic-
tor of several outcomes [33,35,56], relatively little is known
about the effect of individual disease combinations on the out-
come of interest [50,52,53]. A few authors studied the effect of
combinations of individual diseases on disability [56,57]. They
showed that the effects of some disease combinations on dis-
ability were additive, whereas the effects of other disease com-
binations were synergistic, leading to more disability than
would be expected on the basis of addition. For this type of re-
search, which studies the prognosis of comorbidity and multi-
morbidity, large numbers of patients are required. Continuing
this research to include several index diseases and outcomes
could lead to the identification of comorbid conditions that are
particularly relevant for one specific index disease and the cho-
sen outcome. These comorbid conditions can subsequently be
used to develop disease-specific comorbidity measures.
The development of a comorbidity measure is influenced
by the population and outcome used [52]. For the Charlson
index it was shown that other weights would have been ap-
plied if it had been developed for a different population
[8,9,12]. Weights were based on the relative risk of dying,
and were used to indicate that not all comorbid conditions
have the same impact on the total comorbidity burden. What
would have happened if they had chosen another outcome
measure? It is likely that the weights would have been very
different. Take, for example, osteoarthritis. Weights derived
from regression analysis, using mortality as the outcome,
will probably be very different from those using mobility as
the outcome. These influences should be taken into account
when selecting an appropriate comorbidity measure.
Commonly used methods to obtain data that can be used
to score comorbidity are interviews, questionnaires, physi-
cal examinations, medical chart reviews, and coded data-
bases. The completeness of data obtained from interviews
and questionnaires depends on the ability of patients to ade-
quately recall the diseases they suffer from. This ability is
strongly influenced by the knowledge and memory of the
patient [6]. Although the source of information, i.e., the pa-
tient, is the same for interviews and questionnaires, the cor-
relation between scores based on interviews, and question-
naires ranges from 0.45 to 0.63 [6,52]. One advantage of
these two methods is that they are easy to apply in settings
in which there is no access to detailed patient records. Med-
ical chart reviews probably yield the most complete data
[22,58–60], provided that all charts that exist for one patient
are collected. Collecting all the charts and screening the
content for relevant data can be rather time consuming, thus
increasing the administrative burden. The usefulness of
coded databases for the assessment of comorbidity has been
the subject of several articles [59,61–63]. A major problem
is the limited space available for recording present diseases,
and when there are multiple diagnoses, a selection must be
made. More serious diseases, the disease for which the pa-
tient was admitted, and complications during hospitalization
have a higher chance of being recorded than chronic condi-
tions [15,59], introducing substantial bias. Increasing the
number of diagnoses might limit this bias, although it is
doubtful whether this will solve the problem [59]. Studies
comparing scores derived from medical records with those
derived from large ICD-9 code-based administrative data-
bases, showed that date derived from medical records are
more complete than those derived from administrative data-
bases, especially with regard to asymptomatic diseases
[14,22,52,59,62]. Administrative databases yield data for
large patient groups, but for smaller studies data from medi-
cal records should preferably be used, although data from
interviews or questionnaires are a useful alternative.
In conclusion, the Charlson Index, the CIRS, the ICED,
and the Kaplan Index are valid and reliable methods to mea-
sure comorbidity that can be used in clinical research. For the
other indexes, insufficient data on the clinimetric properties
are available to assess their validity and reliability. When
mortality is the outcome of interest, the Charlson Index has
been studied most extensively, and there are several adapta-
tions available. An advantage of the CIRS is the close resem-
blance to common clinical practice: it is structured according
to clinically relevant body systems and uses a clear severity
ranking that is clinically sound. Given the good validity and
reliability, the CIRS seems a very useful comorbidity mea-
sure in clinical research. The ICED is the only measure in-
cluded in this review that has a two-dimensional structure,
measuring both pathophysiologic disease severity and dis-
ability. This might be particularly useful in studies in which
mortality and disability are the outcomes of interest. The Ka-
plan index was specifically developed for use in diabetes re-
search, and contains clinically relevant information. It makes
a distinction between vascular and nonvascular comorbidity,
and uses severity rankings based on parameters derived from
common clinical practice. This good face validity, together
with the good psychometric properties, makes the Kaplan In-
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